Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of ACT001 plus whole-brain radiotherapy in small cell lung cancer with brain metastases
CTR20253399Phase 3Active
- Sponsor
- Tianjin Xinyi Shangde Biomedical Technology
- Start
- Sep 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dimethylaminomicheliolide in small cell lung cancer (SCLC), brain metastases, sponsored by Tianjin Xinyi Shangde Biomedical Technology. Started Sep 2025; status: active.
02
Drugs
dimethylaminomicheliolide
03
Conditions
small cell lung cancer (SCLC)brain metastases
Beyond the preview
Go deeper on CTR20253399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253399.